Brokerages Expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) Will Post Quarterly Sales of $4.29 Billion

Equities research analysts predict that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will announce $4.29 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Teva Pharmaceutical Industries’ earnings. The highest sales estimate is $4.46 billion and the lowest is $4.13 billion. Teva Pharmaceutical Industries posted sales of $4.45 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 3.6%. The business is expected to report its next quarterly earnings results on Wednesday, February 9th.

On average, analysts expect that Teva Pharmaceutical Industries will report full year sales of $16.07 billion for the current fiscal year, with estimates ranging from $15.91 billion to $16.24 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $16.31 billion, with estimates ranging from $16.05 billion to $16.59 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, October 27th. The company reported $0.59 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.65 by ($0.06). The business had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $4.05 billion. Teva Pharmaceutical Industries had a net margin of 4.47% and a return on equity of 23.53%. Teva Pharmaceutical Industries’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.56 EPS.

Several equities research analysts have recently weighed in on the stock. Raymond James downgraded shares of Teva Pharmaceutical Industries from an “outperform” rating to a “market perform” rating in a research note on Thursday, October 28th. TheStreet raised shares of Teva Pharmaceutical Industries from a “d+” rating to a “c” rating in a research note on Wednesday, October 27th. Four research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $11.50.

Shares of TEVA opened at $9.17 on Friday. Teva Pharmaceutical Industries has a twelve month low of $7.73 and a twelve month high of $13.30. The company has a market cap of $10.11 billion, a P/E ratio of 13.89, a P/E/G ratio of 0.96 and a beta of 1.29. The company has a current ratio of 1.03, a quick ratio of 0.68 and a debt-to-equity ratio of 1.84. The company’s fifty day simple moving average is $8.62 and its 200-day simple moving average is $9.18.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 2.0% in the third quarter. BlackRock Inc. now owns 40,541,845 shares of the company’s stock worth $394,877,000 after purchasing an additional 785,802 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 7.6% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 21,284,555 shares of the company’s stock worth $207,317,000 after purchasing an additional 1,494,519 shares during the last quarter. Menora Mivtachim Holdings LTD. grew its holdings in shares of Teva Pharmaceutical Industries by 19.6% in the third quarter. Menora Mivtachim Holdings LTD. now owns 19,564,520 shares of the company’s stock worth $190,558,000 after purchasing an additional 3,210,560 shares during the last quarter. Phoenix Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 22.7% in the third quarter. Phoenix Holdings Ltd. now owns 14,170,801 shares of the company’s stock worth $138,053,000 after purchasing an additional 2,620,800 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 1.0% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 10,040,407 shares of the company’s stock worth $97,794,000 after purchasing an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 47.76% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets.

Featured Article: What is meant by buying and selling pressure?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.